Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_
_x000D_
#What Is the Estimated Industry Valuation for the Direct Oral Anticoagulants (DOACs) Device Sector?#_x000D_
The market size of the direct oral anticoagulants (DOACs) device has seen substantial growth in the past few years. It is projected to increase from $30.10 billion in 2024 to $32.80 billion in 2025, registering a compound annual growth rate (CAGR) of 9.0%. The growth during the previous period has been driven by factors such as the increasing cases of cardiovascular diseases, higher incidence of atrial fibrillation, growing understanding of stroke prevention, rise in anticoagulant prescriptions, and the expansion of the elderly population._x000D_
_x000D_
In the forthcoming years, the market size for the direct oral anticoagulants (DOACs) device is projected to experience robust expansion. The value of this market is forecasted to reach $45.65 billion in 2029, growing at a compound annual growth rate (CAGR) of 8.6%. The surge in growth during the forecast period can be accredited to the increasing acceptance of personalized medicine, a change in preference for anticoagulant management at home, an escalated demand for quick diagnostic tools, growing knowledge about stroke prevention, and the development of healthcare infrastructure in emerging markets. Key trends foreseen during this period are the inclusion of smart sensors in monitoring devices, the creation of point-of-care direct oral anticoagulant testing tools, constant innovation in drug delivery methods, integration into recurring clinical procedures, and advances in technology relating to patient compliance tools._x000D_
_x000D_
#Download The Free Sample Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=27281&type=smp_x000D_
_x000D_
#What Forces Are Driving The Growth Of The Direct Oral Anticoagulants (DOACs) Device Market?#_x000D_
The surge in cardiovascular diseases is anticipated to fuel the expansion of the direct oral anticoagulants (DOACs) device market in the future. These cardiovascular disorders, which include a variety of conditions that affect the heart and blood vessels, often result in complications such as heart attacks, strokes, or other vascular system issues. Factors like sedentary lifestyles, weight gain, high blood pressure, and deteriorating cardiovascular function over time are leading to a rise in these disorders. Direct oral anticoagulants (DOACs) assist in managing these disorders by effectively reducing the stroke and blood clot risks in patients suffering from atrial fibrillation and providing steady anticoagulation, eliminating the need for regular blood tests. For example, the American Heart Association, a US-based nonprofit organization, reported that cardiovascular disease accounted for 941,652 fatalities in the US in 2022, a rise of over 10,000 from the 931,578 deaths reported in 2021. Consequently, the escalating occurrence of cardiovascular diseases, is stimulating the direct oral anticoagulants (DOACs) device market’s progression._x000D_
_x000D_
#How Is The Direct Oral Anticoagulants (DOACs) Device Industry Segmented Across Key Parameters?#_x000D_
The direct oral anticoagulants (DOACs) device market covered in this report is segmented_x000D_
_x000D_
1) By Product: Factor Xa Inhibitors, Direct Thrombin Inhibitors_x000D_
2) By Disease: Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Heart Attacks, Post-Surgical Thromboprophylaxis, Other Diseases_x000D_
3) By Application: Stroke Prevention, Venous Thromboembolism Prevention, Treatment Of Acute Thrombotic Events, Long-Term Prophylaxis, Other Applications_x000D_
4) By End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Homecare Settings, Other End Users_x000D_
_x000D_
Subsegments:_x000D_
1) By Factor Xa Inhibitors: Rivaroxaban Monitoring Devices, Apixaban Monitoring Devices, Edoxaban Monitoring Devices, Betrixaban Monitoring Devices_x000D_
2) By Direct Thrombin Inhibitors: Dabigatran Etexilate, Dabigatran Mesylate_x000D_
_x000D_
#What Notable Trends Are Shaping The Direction Of The Direct Oral Anticoagulants (DOACs) Device Market?#_x000D_
Prominent firms in the direct oral anticoagulants (DOACs) market are prioritizing the creation of innovative solutions, such as automated coagulation assays, to enhance precision, productivity, and uniformity in monitoring direct oral anticoagulant levels in clinical labs. Automated coagulation assays are machine-conducted lab tests that determine the speed of blood clotting, assisting in the identification of bleeding or clotting issues. For instance, in February 2024, Roche Holding AG, a pharmaceutical firm based in Switzerland, introduced three novel coagulation tests developed specifically for Factor Xa inhibitors. These tests augment the capacity of clinicians to correctly assess the anticoagulation condition of patients consuming direct Factor Xa inhibitors like rivaroxaban and apixaban. These tests facilitate clinical decision-making by accurately gauging the anti-Xa activity of apixaban, edoxaban, rivaroxaban, and heparin in critical situations such as bleeding, overdose, or immediate surgery. Through the utilization of Roche’s reagent cartridge technology on cobas t analyzers, these automated tests provide top-quality results, reduce manual input, and accelerate lab workflow efficiency._x000D_
_x000D_
#Which Companies Currently Dominate The Competitive Landscape In The Direct Oral Anticoagulants (DOACs) Device Industry?#_x000D_
Major companies operating in the direct oral anticoagulants (DOACs) device market are Pfizer Inc., Roche Diagnostics Corporation, Bristol-Myers Squibb Company, Siemens Healthcare GmbH, Becton Dickinson And Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Daiichi Sankyo Co. Ltd, Sysmex Corporation, Dr. Reddy’s Laboratories Limited, Werfen S.A., Alembic Pharmaceuticals Limited, Diagnostica Stago SAS, Helena Laboratories Corporation, iLine Microsystems S.L., Technoclone GmbH, Anthos Therapeutics Inc., FLoBio LLC, Perosphere Technologies Inc., and DOASENSE GmbH. _x000D_
_x000D_
#Get The Full Report Here:#_x000D_
_x000D_
#Which Geographic Regions Are Driving Demand In The Direct Oral Anticoagulants (DOACs) Device Market?#_x000D_
North America was the largest region in the direct oral anticoagulants (DOACs) device market in 2024. The regions covered in the direct oral anticoagulants (DOACs) device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Request For A Customized Report:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=27281&type=smp_x000D_
_x000D_
#About The Business Research Company:#_x000D_
_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Asia +44 7882 955267 & +91 8897263534_x000D_
Europe +44 7882 955267_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model